vorinostat has been researched along with Hypokalemia in 3 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Hypokalemia: Abnormally low potassium concentration in the blood. It may result from potassium loss by renal secretion or by the gastrointestinal route, as by vomiting or diarrhea. It may be manifested clinically by neuromuscular disorders ranging from weakness to paralysis, by electrocardiographic abnormalities (depression of the T wave and elevation of the U wave), by renal disease, and by gastrointestinal disorders. (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " A phase I study was initiated to establish the recommended phase 2 dose of sorafenib combined with vorinostat in patients with unresectable hepatocellular carcinoma." | 9.30 | Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma. ( Bandyopadhyay, D; Bose, P; Deng, X; Dent, P; Gordon, SW; Kmieciak, M; Lee, HM; Matherly, SC; McGuire, WP; Nguyen, T; Poklepovic, AS; Roberts, JD; Ryan, AA; Shafer, DA; Shrader, EE; Sterling, RK; Tombes, MB, 2019) |
| " A phase I study was initiated to establish the recommended phase 2 dose of sorafenib combined with vorinostat in patients with unresectable hepatocellular carcinoma." | 5.30 | Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma. ( Bandyopadhyay, D; Bose, P; Deng, X; Dent, P; Gordon, SW; Kmieciak, M; Lee, HM; Matherly, SC; McGuire, WP; Nguyen, T; Poklepovic, AS; Roberts, JD; Ryan, AA; Shafer, DA; Shrader, EE; Sterling, RK; Tombes, MB, 2019) |
| "Vorinostat is a histone deacetylase inhibitor used in the treatment of recurrent or persistent cases of cutaneous T-cell lymphoma (CTCL)." | 4.88 | QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature. ( Lynch, DR; Newby, LK; Washam, JB, 2012) |
| "Vorinostat was administered orally daily starting at 180 mg/m(2)/d with escalations planned in 30% increments." | 2.75 | Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. ( Adamson, PC; Ames, MM; Blaney, SM; Fouladi, M; Gilbertson, RJ; Ingle, AM; Park, JR; Reid, JM; Schaiquevich, P; Speights, R; Stewart, CF; Sun, J; Zwiebel, J, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gordon, SW | 1 |
| McGuire, WP | 1 |
| Shafer, DA | 1 |
| Sterling, RK | 1 |
| Lee, HM | 1 |
| Matherly, SC | 1 |
| Roberts, JD | 1 |
| Bose, P | 1 |
| Tombes, MB | 1 |
| Shrader, EE | 1 |
| Ryan, AA | 1 |
| Kmieciak, M | 1 |
| Nguyen, T | 1 |
| Deng, X | 1 |
| Bandyopadhyay, D | 1 |
| Dent, P | 1 |
| Poklepovic, AS | 1 |
| Fouladi, M | 1 |
| Park, JR | 1 |
| Stewart, CF | 1 |
| Gilbertson, RJ | 1 |
| Schaiquevich, P | 1 |
| Sun, J | 1 |
| Reid, JM | 1 |
| Ames, MM | 1 |
| Speights, R | 1 |
| Ingle, AM | 1 |
| Zwiebel, J | 1 |
| Blaney, SM | 1 |
| Adamson, PC | 1 |
| Lynch, DR | 1 |
| Washam, JB | 1 |
| Newby, LK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma[NCT01075113] | Phase 1 | 16 participants (Actual) | Interventional | 2010-08-10 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for vorinostat and Hypokalemia
| Article | Year |
|---|---|
QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature.
Topics: Antineoplastic Agents; Doxepin; Electrocardiography; Histone Deacetylase Inhibitors; Humans; Hydroxa | 2012 |
2 trials available for vorinostat and Hypokalemia
| Article | Year |
|---|---|
Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemical and Drug I | 2019 |
Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2010 |